Jean Terrier: The Relationship Between DOAC Plasma Concentrations and Clinical Outcomes
Jean Terrier, Clinical Pharmacologist and Toxicologist at University of Rhode Island, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Should we publish neutral results?
In clinical research, positive findings often receive the most attention.
But what about studies showing no significant association?
In our recent study – ‘Relevance and limitations of clinical follow-up in a pharmacokinetic study on direct oral anticoagulants’ — conducted within the OptimAT cohort at Geneva University Hospitals, we explored the relationship between DOAC plasma concentrations (apixaban and rivaroxaban) and clinical outcomes over 2 years.
Importantly, the analysis of associations between drug exposure and clinical events was a secondary objective of the OptimAT study.
In 200 hospitalized patients, we analyzed AUC, C-max, and C-trough, and recorded ischemic, thromboembolic, and bleeding events during 2 years follow-up.
What did we observe?
We found no significant association between:
- High apixaban/rivaroxaban plasma concentrations and bleeding events
- Low apixaban/rivaroxaban plasma concentrations and ischemic/thromboembolic events
These are neutral findings – and they matter.
Of course, the study had limitations — limited statistical power due to sample size and a high rate of treatment modifications (41%) reducing the number of evaluable patients.
It is also important to highlight that larger and more recent studies have since reported clearer associations between DOAC concentrations and clinical outcomes.
Our findings do not contradict these data; they reflect the constraints of a pharmacokinetic study not primarily designed for clinical endpoint assessment.
So why publish neutral results?
Because they:
- Help reduce publication bias
- Provide a more balanced and transparent evidence base
- Contribute valuable data for future meta-analyses
- Strengthen scientific integrity and reproducibility
Science advances not only through significant results, but through complete and honest reporting.
Huge thanks to my co-author Pauline Gosselin for her outstanding work in ensuring a rigorous two-year follow-up of all patients, Christophe Combescure, Pierre Fontana, Youssef Daali, and Jean-Luc Reny, and the entire OptimAT Study Team, for their rigorous work, collaboration, and commitment to high-quality clinical research.”
Title: Relevance and limitations of clinical follow-up in a pharmacokinetic study on direct oral anticoagulants
Authors: Jean Terrier, Pauline Gosselin, Christophe Combescure, Pierre Fontana, Youssef Daali, Jean-Luc Reny
Read the Full Article on Frontiers in Pharmacology.
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 4, 2026, 15:11Rishiraj Sinha: Why Trust Matters More Than Knowledge in Blood Donor Engagement
-
Mar 4, 2026, 15:08Nico Gagelmann: Honored to Receive the Young European Hematology Association Award
-
Mar 4, 2026, 14:45Rafael Demarchi Malgor: New Clinical Practice Guideline on Upper Extremity Deep Venous Thrombosis
-
Mar 4, 2026, 14:44Peter Zdziarski: From a Small Message Board to a Global Glanzmann Thrombasthenia Community
-
Mar 4, 2026, 14:36Abdul Mannan: A Practical Guide to Anticoagulation Stewardship
-
Mar 4, 2026, 14:21Midhuna Krishnan: Simplifying Doppler Effect and Ultrasonography Using the Feynman Method
-
Mar 4, 2026, 14:19Priyanshi Pachauri: Looking Beyond Symptomatic Treatment in Iron Deficiency Anemia
-
Mar 4, 2026, 14:16Augustina Isioma Ikusemoro: Can People with Diabetes Donate Blood?
-
Mar 4, 2026, 14:13Christophe Dubois: What if Blood Platelets Played an Important Role in Venous Thrombosis?